Treatment of Behavioral and Psychological Symptoms of Alzheimer's Disease

被引:61
作者
Corbett, Anne [1 ]
Smith, Jessica [1 ]
Creese, Byron [2 ]
Ballard, Clive [2 ]
机构
[1] Alzheimers Soc UK, London, England
[2] Kings Coll London, Wolfson Ctr Age Related Dis, London SE1 1UL, England
关键词
Alzheimer's disease; Symptoms; BPSD; Treatment; Atypical antipsychotics; Aggression; Agitation; Psychosis; Risperidone; Pain; Infection; Assessment; Psychological interventions; Person-centered care; Staff training; PLACEBO-CONTROLLED TRIALS; CLUSTER-RANDOMIZED-TRIAL; NEUROPSYCHIATRIC SYMPTOMS; DOUBLE-BLIND; PSYCHOTIC SYMPTOMS; DEMENTIA SUFFERERS; NEUROLEPTIC DRUGS; CLINICAL-TRIAL; CACHE COUNTY; AGITATION;
D O I
10.1007/s11940-012-0166-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Behavioral and psychological symptoms of dementia (BPSD) are frequent amongst people with Alzheimer's disease (AD) and other dementias, commonly confer risk to that person and others, and present a significant management challenge for clinicians. There is increasing evidence to support the value of simple psychological interventions and the treatment of pain as a first-line management strategy prior to pharmacotherapy. The most widely prescribed pharmacological treatments-atypical antipsychotics-have a modest but significant beneficial effect in the short-term treatment of aggression (over 612 weeks) but limited benefits in longer-term therapy. In addition, there have been increasing concerns regarding the potential for serious adverse outcomes, including stroke and death. The potential pharmacologic alternatives to atypical antipsychotics with the most encouraging preliminary evidence include memantine, carbamazepine, citalopram, and prazosin. Large, prospective, randomized placebo-controlled trials are needed to establish the role of these agents as clinical therapies for the treatment of BPSD.
引用
收藏
页码:113 / 125
页数:13
相关论文
共 64 条
[1]   Delusion Symptoms and Response to Antipsychotic Treatment are Associated with the 5-HT2A Receptor Polymorphism (102T/C) in Alzheimer's Disease: A 3-Year Follow-up Longitudinal Study [J].
Angelucci, Francesco ;
Bernardini, Sergio ;
Gravina, Paolo ;
Bellincampi, Lorenza ;
Trequattrini, Alberto ;
Di Iulio, Fulvia ;
Vanni, Diego ;
Federici, Giorgio ;
Caltagirone, Carlo ;
Bossu, Paola ;
Spalletta, Gianfranco .
JOURNAL OF ALZHEIMERS DISEASE, 2009, 17 (01) :203-211
[2]  
[Anonymous], 2009, USE ANTIPSYCHOTIC ME
[3]  
[Anonymous], 2008, ALZH DIS INT FACT SH
[4]  
[Anonymous], 2008, INF HEALTHC PROF CON
[5]  
[Anonymous], 2005, 1372005 US FDA CTR D
[6]   Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial [J].
Ballard, C ;
Margallo-Lana, M ;
Juszczak, E ;
Douglas, S ;
Swann, A ;
Thomas, A ;
O'Brien, J ;
Everratt, A ;
Sadler, S ;
Maddison, C ;
Lee, L ;
Bannister, C ;
Elvish, R ;
Jacoby, R .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7496) :874-877
[7]   Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities [J].
Ballard, C ;
Powell, I ;
James, I ;
Reichelt, K ;
Myint, P ;
Potkins, D ;
Bannister, C ;
Lana, M ;
Howard, R ;
O'Brien, J ;
Swann, A ;
Robinson, D ;
Shrimanker, J ;
Barber, R .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2002, 17 (02) :140-145
[8]  
Ballard C, 2000, ANN NEUROL, V48, P868, DOI 10.1002/1531-8249(200012)48:6<868::AID-ANA7>3.0.CO
[9]  
2-0
[10]  
Ballard CG, 1996, BRIT MED J, V312, P947